These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 2973433)

  • 21. C3 convertase of the human alternative pathway of complement: modulation of enzyme activity and stability by mouse monoclonal antibodies to Bb.
    Fishelson Z; Müller-Eberhard HJ
    Eur J Immunol; 1987 Feb; 17(2):303-4. PubMed ID: 3644748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade.
    Krettli AU; Pontes de Carvalho LC
    Clin Exp Immunol; 1985 Nov; 62(2):270-7. PubMed ID: 3910312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
    Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
    Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
    Kazatchkine MD; Fearon DT; Austen KF
    J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
    Strunk RC; Giclas PC
    J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
    [No Abstract]   [Full Text] [Related]  

  • 32. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B.
    Joiner K; Sher A; Gaither T; Hammer C
    Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6593-7. PubMed ID: 2944112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
    Baker PJ; Adler S; Yang Y; Couser WG
    J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evasion of Trypanosoma cruzi from complement lysis.
    Kipnis TL; da Silva WD
    Braz J Med Biol Res; 1989; 22(1):1-16. PubMed ID: 2667667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steady state relations between control proteins regulating the formation of the alternative pathway C3 convertase.
    Reeve J; Woo PM
    Immunology; 1982 Aug; 46(4):859-66. PubMed ID: 6921154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases.
    Rimoldi MT; Sher A; Heiny S; Lituchy A; Hammer CH; Joiner K
    Proc Natl Acad Sci U S A; 1988 Jan; 85(1):193-7. PubMed ID: 3277170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.